Go Pro
→ I don't write about politics. Until today. (From American Alternative) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$979.76
-1.1%		$936.77
$661.85
▼
$1,072.75
$61.97B0.47239,270 shs235,284 shs
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$104.91
$103.67
$38.81
▼
$104.98
$20.03B1.413.55 million shsN/A
Moderna, Inc. stock logo
MRNA
Moderna
$143.77
-2.0%		$94.93
$22.28
▼
$176.66
$58.56B1.134.32 million shs8.39 million shs
Natera, Inc. stock logo
NTRA
Natera
$350.78
+2.6%		$300.35
$157.43
▼
$351.78
$49.27B1.541.07 million shs1.77 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
-1.09%-2.71%+15.09%+9.81%+29.46%
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.00%0.00%0.00%0.00%+96.35%
Moderna, Inc. stock logo
MRNA
Moderna
-1.99%+2.45%+127.05%+132.64%+502.05%
Natera, Inc. stock logo
NTRA
Natera
+2.63%+8.22%+13.18%+54.91%+103.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$979.76
-1.1%		$936.77
$661.85
▼
$1,072.75
$61.97B0.47239,270 shs235,284 shs
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$104.91
$103.67
$38.81
▼
$104.98
$20.03B1.413.55 million shsN/A
Moderna, Inc. stock logo
MRNA
Moderna
$143.77
-2.0%		$94.93
$22.28
▼
$176.66
$58.56B1.134.32 million shs8.39 million shs
Natera, Inc. stock logo
NTRA
Natera
$350.78
+2.6%		$300.35
$157.43
▼
$351.78
$49.27B1.541.07 million shs1.77 million shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
-1.09%-2.71%+15.09%+9.81%+29.46%
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.00%0.00%0.00%0.00%+96.35%
Moderna, Inc. stock logo
MRNA
Moderna
-1.99%+2.45%+127.05%+132.64%+502.05%
Natera, Inc. stock logo
NTRA
Natera
+2.63%+8.22%+13.18%+54.91%+103.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
2.88
Moderate Buy$1,158.6118.25% Upside
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
1.95
Reduce$98.21-6.38% Downside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$76.72-46.64% Downside
Natera, Inc. stock logo
NTRA
Natera
2.83
Moderate Buy$330.83-5.69% Downside

Current Analyst Ratings Breakdown

Latest EXAS, ARGX, MRNA, and NTRA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/9/2026
Natera, Inc. stock logo
NTRA
Natera
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$290.00 ➝ $435.00
9/8/2026
Natera, Inc. stock logo
NTRA
Natera
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$385.00
9/8/2026
Natera, Inc. stock logo
NTRA
Natera
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform ➝ Buy
9/8/2026
Natera, Inc. stock logo
NTRA
Natera
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$385.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$81.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Sell
9/3/2026
argenex SE stock logo
ARGX
argenex
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$1,150.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeNeutral ➝ Sell$40.00 ➝ $81.00
8/31/2026
argenex SE stock logo
ARGX
argenex
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$1,230.00 ➝ $1,250.00
8/28/2026
Moderna, Inc. stock logo
MRNA
Moderna
CLSA logo
CLSA
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeOutperform
(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$4.25B14.43$21.10 per share46.43$118.34 per share8.28
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$3.25B6.17$1.27 per share82.83$12.58 per share8.34
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B29.53N/AN/A$22.14 per share6.49
Natera, Inc. stock logo
NTRA
Natera
$2.71B18.68N/AN/A$12.38 per share28.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$1.29B$26.0437.6326.291.0232.19%43.59%36.66%N/A
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$207.95M-$1.10N/A209.822.02-6.40%0.53%0.22%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$208.16M-$1.36N/A35,078.00N/A-7.11%-11.38%-7.87%11/5/2026 (Estimated)

Latest EXAS, ARGX, MRNA, and NTRA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Natera, Inc. stock logo
NTRA
Natera
-$0.4939-$0.47+$0.0239-$0.47$661.24 million$752.75 million
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
7/21/2026Q2 2026
argenex SE stock logo
ARGX
argenex
$5.86$7.32+$1.46$7.32$1.45 billion$1.54 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.97
2.43
2.17
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
Natera, Inc. stock logo
NTRA
Natera
N/A
3.00
2.85

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
88.82%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Natera, Inc. stock logo
NTRA
Natera
99.90%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
1.20%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Natera, Inc. stock logo
NTRA
Natera
5.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,86362.56 million61.04 millionOptionable
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
7,200190.89 million188.60 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
6,140144.14 million136.87 millionOptionable

Recent News About These Companies

Natera (NASDAQ:NTRA) Reaches New 52-Week High - What's Next?
September 15 at 10:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-natera-nasdaq-ntra-reaches-new-52-week-high-whats-next-2026-09-15/
Natera, Inc. (NASDAQ:NTRA) Given Average Rating of "Moderate Buy" by Brokerages
September 15 at 2:28 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31023807
Natera, Inc. (NASDAQ:NTRA) Given Average Rating of "Moderate Buy" by Analysts
September 15 at 2:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-natera-inc-nasdaq-ntra-given-average-rating-of-moderate-buy-by-analysts-2026-09-15/
This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters.
September 14 at 9:30 AM  |  fool.comhttps://www.fool.com/investing/2026/09/14/surprising-stock-has-been-stanley-druckenmillers/
NewEdge Advisors LLC Has $6.44 Million Stake in Natera, Inc. $NTRA
September 14 at 4:16 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-newedge-advisors-llc-has-644-million-stake-in-natera-inc-ntra-2026-09-14/
Natera, Inc. $NTRA Shares Acquired by IFP Advisors Inc
September 13 at 4:00 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-acquired-by-ifp-advisors-inc-2026-09-13/
Natera, Inc. $NTRA Shares Sold by National Pension Service
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-sold-by-national-pension-service-2026-09-12/
Bernstein Remains a Buy on Natera (NTRA)
September 11, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NTRA/pressreleases/4531954/bernstein-remains-a-buy-on-natera-ntra/
Natera, Inc. $NTRA Stake Raised by Engineers Gate Manager LP
September 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-stake-raised-by-engineers-gate-manager-lp-2026-09-11/
Natera (NASDAQ:NTRA) Research Coverage Started at Rothschild & Co Redburn
September 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31015834
UBS Group Forecasts Strong Price Appreciation for Natera (NASDAQ:NTRA) Stock
September 11, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31015836
BlueCrest Capital Management Ltd Purchases New Holdings in Natera, Inc. $NTRA
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bluecrest-capital-management-ltd-purchases-new-holdings-in-natera-inc-ntra-2026-09-10/
Amundi Buys 9,338 Shares of Natera, Inc. $NTRA
September 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-amundi-buys-9338-shares-of-natera-inc-ntra-2026-09-10/
3 reasons investors love Natera (NTRA)
September 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/3-reasons-investors-love-natera-ntra/ar-AA2bTSkZ
UBS Group Begins Coverage on Natera (NASDAQ:NTRA)
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-ubs-group-begins-coverage-on-natera-nasdaq-ntra-2026-09-09/
Billionaire Stanley Druckenmiller’s Largest Holding Is a Healthcare Firm That Has Surged Nearly 10x in Three Years
September 9, 2026  |  dailyhodl.comD
C WorldWide Group Holding A S Sells 20,000 Shares of Natera, Inc. $NTRA
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-c-worldwide-group-holding-a-s-sells-20000-shares-of-natera-inc-ntra-2026-09-09/
Natera (NASDAQ:NTRA) Rating Increased to Strong-Buy at Rothschild & Co Redburn
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-natera-nasdaq-ntra-rating-increased-to-strong-buy-at-rothschild-co-redburn-2026-09-09/
HighTower Advisors LLC Increases Stake in Natera, Inc. $NTRA
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hightower-advisors-llc-increases-stake-in-natera-inc-ntra-2026-09-09/
Natera, Inc. $NTRA Shares Acquired by Hsbc Holdings PLC
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-shares-acquired-by-hsbc-holdings-plc-2026-09-09/
Natera, Inc. $NTRA Position Increased by Saudi Central Bank
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-natera-inc-ntra-position-increased-by-saudi-central-bank-2026-09-08/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Moderna logo displayed in a laboratory setting with a vaccine vial, petri dishes, and a microscope.
Moderna’s 177% Surge Has Investors Asking What Comes Next
By Sam Quirke | August 21, 2026
Illustration of a vial with an upward stock price chart and DNA double helix against a city skyline, symbolizing biotech growth.
2 Biotech Stocks Shaping Up for Major Breakouts
By Ryan Hasson | August 22, 2026
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
argenex stock logo

argenex NASDAQ:ARGX

$979.76 -10.78 (-1.09%)
Closing price 09/15/2026 04:00 PM Eastern
Extended Trading
$979.61 -0.15 (-0.02%)
As of 09/15/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Exact Sciences stock logo

Exact Sciences NASDAQ:EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Moderna stock logo

Moderna NASDAQ:MRNA

$143.77 -2.92 (-1.99%)
Closing price 09/15/2026 04:00 PM Eastern
Extended Trading
$143.99 +0.22 (+0.15%)
As of 09/15/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Natera stock logo

Natera NASDAQ:NTRA

$350.78 +8.99 (+2.63%)
Closing price 09/15/2026 04:00 PM Eastern
Extended Trading
$355.62 +4.84 (+1.38%)
As of 09/15/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas